8 Most Undervalued Healthcare Stocks to Buy According to Analysts
Healthcare prices and expenditures have been rising in the United States.
Genmab A/S (GMAB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 3,092,144 | $64,533,045 | +138% | 0.01% |
| 2. | Orbis Investment Management William B. Gray | 2,815,562 | $58,760,779 | +68% | 0.31% |
| 3. | Deep Track Capital David Kroin | 2,000,000 | $41,740,000 | 1.55% | |
| 4. | Renaissance Technologies Jim Simons | 1,926,150 | $40,198,750 | +8% | 0.05% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,653,500 | $34,508,545 | +169% | 0.07% |
Institutional Investors' Holdings
News See All
7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
Genmab A/S (GMAB): A Bull Case Theory
We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on GMAB.
10 Cash-Rich Undervalued Stocks To Invest In
Currently, big tech and high-growth stocks dominate the stock market, making up a much larger share of the broader market than they have historically.
15 Stocks That Will Go to The Moon According to Analysts
While stocks initially fell based on worries regarding Trump tariffs on America’s major trading partners, major indexes recovered from their initial losses as the President delayed tariffs on Mexico...
12 Best Growth Stocks to Invest In According to Analysts
Companies experiencing above-average earnings growth, which is often fueled by innovations and market expansions, are known as growth stocks.
Genmab A/S (NASDAQ:GMAB) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Genmab Full Year 2024 Financial Results Conference Call. As a reminder, this conference call is being recorded.
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
Leerink does not expect Johnson & Johnson (JNJ) to exercise its option to develop GMAB's GEN3014, a treatment candidate for relapsed/refractory multiple myeloma patients.
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
12 High Growth International Stocks to Invest in Now
On January 15, Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025.
Billionaire Hedge Funds
